DOP2017000268A - Metodos y kits para tratar depresion - Google Patents

Metodos y kits para tratar depresion

Info

Publication number
DOP2017000268A
DOP2017000268A DO2017000268A DO2017000268A DOP2017000268A DO P2017000268 A DOP2017000268 A DO P2017000268A DO 2017000268 A DO2017000268 A DO 2017000268A DO 2017000268 A DO2017000268 A DO 2017000268A DO P2017000268 A DOP2017000268 A DO P2017000268A
Authority
DO
Dominican Republic
Prior art keywords
methods
treatment
kits
depression
treat depression
Prior art date
Application number
DO2017000268A
Other languages
English (en)
Spanish (es)
Inventor
Singh Jaskaran
CAERS Ivo
DALY Ella
Drevets Wayne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of DOP2017000268A publication Critical patent/DOP2017000268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DO2017000268A 2015-05-20 2017-11-17 Metodos y kits para tratar depresion DOP2017000268A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
DOP2017000268A true DOP2017000268A (es) 2018-04-15

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000268A DOP2017000268A (es) 2015-05-20 2017-11-17 Metodos y kits para tratar depresion

Country Status (20)

Country Link
US (1) US20160338977A1 (enExample)
EP (1) EP3297618A4 (enExample)
JP (1) JP2018515557A (enExample)
KR (1) KR20180008634A (enExample)
CN (1) CN107735081A (enExample)
AU (3) AU2016263598A1 (enExample)
CA (1) CA2986477A1 (enExample)
CL (1) CL2017002904A1 (enExample)
CO (1) CO2017011564A2 (enExample)
DO (1) DOP2017000268A (enExample)
EA (1) EA201792545A1 (enExample)
EC (1) ECSP17077930A (enExample)
GT (1) GT201700246A (enExample)
HK (1) HK1252937A1 (enExample)
IL (1) IL255463A (enExample)
MA (1) MA42135A (enExample)
MX (1) MX2017014797A (enExample)
PE (1) PE20180260A1 (enExample)
PH (1) PH12017502103A1 (enExample)
WO (1) WO2016187491A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3813807A1 (en) * 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
KR20230018448A (ko) * 2020-05-28 2023-02-07 얀센 파마슈티카 엔.브이. 우울증의 치료 방법
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
EP2983787B1 (en) * 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
KR20170054470A (ko) * 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
MX2017014797A (es) 2018-02-15
GT201700246A (es) 2019-07-29
PE20180260A1 (es) 2018-02-05
EA201792545A1 (ru) 2018-05-31
WO2016187491A1 (en) 2016-11-24
PH12017502103A1 (en) 2018-05-07
IL255463A (en) 2018-01-31
AU2016263598A1 (en) 2017-11-23
CN107735081A (zh) 2018-02-23
MA42135A (fr) 2018-03-28
CO2017011564A2 (es) 2018-04-19
JP2018515557A (ja) 2018-06-14
AU2021215155A1 (en) 2021-09-02
EP3297618A1 (en) 2018-03-28
KR20180008634A (ko) 2018-01-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
HK1252937A1 (zh) 2019-06-06
CL2017002904A1 (es) 2018-04-20
ECSP17077930A (es) 2018-02-28
EP3297618A4 (en) 2019-01-23
CA2986477A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
DOP2017000268A (es) Metodos y kits para tratar depresion
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX373187B (es) Terapia de combinación para tratar cáncer.
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
CL2019001258A1 (es) Métodos para tratar el síndrome de alport usando bardoxolona metilo o análogos de la misma.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX387283B (es) Tratamiento del cancer con tg02.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
CO2020007129A2 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).